pheniramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2132	86-21-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: propheniramine prophenpyridamine pyriton tripoton pheniramine maleate pheniramine	One of the HISTAMINE H1 ANTAGONISTS with little sedative action. It is used in treatment of hay fever, rhinitis, allergic dermatoses, and pruritus. Molecular weight: 240.35 Formula: C16H20N2 CLOGP: 2.44 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 16.13 ALOGS: -2.80 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

propheniramine
prophenpyridamine
pyriton
tripoton
pheniramine maleate
pheniramine

One of the HISTAMINE H1 ANTAGONISTS with little sedative action. It is used in treatment of hay fever, rhinitis, allergic dermatoses, and pruritus.

Molecular weight: 240.35
Formula: C16H20N2
CLOGP: 2.44
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 16.13
ALOGS: -2.80
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
75	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	100 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma)	0.37 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Showing 1 to 4 of 4 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
June 8, 1994	FDA	ALCON

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	53.49	32.41	28	543	230971	79512846

Showing 1 to 1 of 1 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	D04AA16	DERMATOLOGICALS ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. Antihistamines for topical use
ATC	R06AB05	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Substituted alkylamines
MeSH PA	D018926	Anti-Allergic Agents
MeSH PA	D000982	Antipruritics
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D018377	Neurotransmitter Agents

Showing 1 to 9 of 9 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Sinus headache	indication	4969004
Dermatographic urticaria	indication	7632005	DOID:743
Vasomotor rhinitis	indication	8229003	DOID:4730
Cough	indication	49727002
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Nasal congestion	indication	68235000
Red eye	indication	75705005
Sneezing	indication	76067001
Common cold	indication	82272006	DOID:10459

Showing 1 to 10 of 171 entries

Previous1 2 3 4 5…18Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.47	Basic
pKa2	4.14	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST			CHEMBL	CHEMBL
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		Ki	5.38	PDSP
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	4.48	CHEMBL

Showing 1 to 3 of 3 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
003388	NDDF
004794	NDDF
105	INN_ID
116546005	SNOMEDCT_US
132-20-7	SECONDARY_CAS_RN
134FM9ZZ6M	UNII
266959	RXNORM
373500002	SNOMEDCT_US
4018472	VANDF
4019888	VUID

Showing 1 to 10 of 25 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Alahist D	HUMAN OTC DRUG LABEL	2	50991-776	TABLET	17.50 mg	ORAL	OTC monograph final	10 sections
Alahist D	HUMAN OTC DRUG LABEL	2	50991-776	TABLET	17.50 mg	ORAL	OTC monograph final	10 sections
ALAHIST DM	HUMAN OTC DRUG LABEL	3	50991-444	LIQUID	12.50 mg	ORAL	OTC monograph final	16 sections
Equate Eye Allergy Relief Drops	HUMAN OTC DRUG LABEL	2	49035-874	SOLUTION/ DROPS	3.15 mg	OPHTHALMIC	ANDA	15 sections
Eye Allergy Relief	HUMAN OTC DRUG LABEL	2	0363-0430	SOLUTION/ DROPS	3.15 mg	OPHTHALMIC	NDA	14 sections
Eye Allergy Relief	HUMAN OTC DRUG LABEL	2	0363-0430	SOLUTION/ DROPS	3.15 mg	OPHTHALMIC	NDA	14 sections
Eye Allergy Relief	HUMAN OTC DRUG LABEL	2	11673-430	SOLUTION/ DROPS	3.15 mg	OPHTHALMIC	NDA	14 sections
Eye Allergy Relief	HUMAN OTC DRUG LABEL	2	11673-430	SOLUTION/ DROPS	3.15 mg	OPHTHALMIC	NDA	14 sections
Eye Allergy Relief	HUMAN OTC DRUG LABEL	2	11822-0552	SOLUTION/ DROPS	3.15 mg	OPHTHALMIC	NDA	14 sections
Eye Allergy Relief	HUMAN OTC DRUG LABEL	2	49035-430	SOLUTION/ DROPS	3.15 mg	OPHTHALMIC	NDA	14 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next